An AI Diagnostics Fund (AIDF) of £21.3m has been prepared for NHS Trusts to procure AI diagnostic imaging technologies.
The aim of newly procured AI technologies is:
The primary aim of the funding is chest xray (CXR) given the ready availability of solutions and the immediate need to address workforce and backlog challenges. However, the scope is targeted to CXR – not limited to it.
NHS Imaging Networks can apply for the funding by September 4th.
The procured solutions are expected to be deployed by the end of 2023, with measurable impact seen as early as Winter 2023/24.
More information on how to apply can be found here.
Oxipit solutions are fully compliant with AIDF procurement requirements. Our solutions are simple to deploy, cost-efficient and offer tangible clinical value for the evaluation timeframe and many years in the future.
ChestLink is the first fully certified autonomous AI solution, which produces final reports for studies without abnormalities. The solution can operate in fully autonomous, as well as semi-autonomous mode (where AI reported studies can be reviewed and approved by a physician). ChestLink offers autonomous reporting for CXRs, other imaging modalities are available upon request. ChestLink is already deployed in 10+ medical institutions. A recent Radiology Journal study outlined the clinical performance and benefits of ChestLink product.
Quality product acts as an AI-powered second reader. In near real time, the product reviews diagnostic images and corresponding reports, identifying potentially missed findings. If clinically significant findings are identified, the product sends a notification to the reporting radiologist to review the study again. The product alerts on clinically significant mistakes only, minimizing distractions and false positive alerts. The product can operate in near-real time (prospective mode) and in retrospective mode (diagnostic quality audit). Oxipit Quality supports CXRs, MSK x-rays, MMG images and CT scans.
CAD solution provide automated assisted diagnostics, with potential findings and heatmap highlights. The solution supports CXR, MSK x-rays, MMG images and CT scans.
CAD application can be combined with Quality and ChestLink products to further boost reporting performance.
Oxipit solutions are easily combined with a single point for deployment.
Excellent deliverability
Oxipit can demonstrate that our ChestLink and ChestEye solutions are ready to deploy, have already been validated in clinical use, and can seamlessly integrate with existing NHS infrastructure with regards to PACS, RIS and common interface requirements.
Clear-cut Costs
Costs have been set out as part of the AIDF programme and those submitted by Oxipit are 2 year total cost of ownership. Customers wishing to enter into 4 year agreements have the option of freezing annual costs.
Significant Savings
Revenue savings at a trust with ChestLink deployed can be expected to be substantial- 50,000 exams autonomously reported would save approximately £1m if an internal cost of up to £20 per exam is assumed.
Joint Deployments
The benefits can be at a single institution or with ICB support, extended to the radiology imaging Network or region. Oxipit licensing is calculated based on the number of exams so there is no restriction on the number of institutions wishing to ‘share’ a deployment.
Long-term Benefits
Investing in Oxipit doesn’t just deliver immediate revenue savings, it also brings greater efficiency and improved accuracy of reporting thanks to ChestEye enhancements which allow the radiology department to process exams more efficiently with the confidence that repeat exams or query results are far less likely. This investment decision represents value for money for the referrer too; with faster and more accurate turnaround.
Strategic NHS Alignment
Experience with clinical partners to date has further convinced the team at Oxipit that ChestEye and ChestLink fit well within the typical clinical routine of standard NHS radiology workflow. By removing overall worklist burden via the automated reporting of all CXR studies found to be normal, as well as providing a QA on all other studies; the Oxipit solution speeds up workflow while supporting radiologists.
Game Changing Technology
This is a game-changing technology which directly addresses the requirements set out in the NHS policy paper, “A plan for digital health and social care” (2022) by digitizing a service and process in order to tackle waiting lists particularly in the face of staff shortages.
Tangible Benefits
Clinical pathway there are no extra steps or alternate workflows required to accommodate ChestLink – radiology departments operates in the same way but with the crucial difference in that a very significant portion of CXR studies will have been automatically taken off the worklist with the reported exam made available for review and/or direct send to PACS, RIS or portals.
We can support NHS clients with sample project plans to help establish the likely Level of Effort required from deploying organizations. Oxipit can work with NHS clients to establish best working practice to share any learning to peer organizations.
By contacting us you acknowledge that we will process yout personal data in accordance with our Privacy Notice, which you may find here.